Skip to content
AnalystLens

Illumina 8-K Report, Financial Results (May 8, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 8, 2025
Period End
May 8, 2025
Security
ILMN
In the record · 2016–202610-K1110-Q338-K167

ILMN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 167 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’17Nov ’17
  2. Material agreement8-K · Sep ’20Sep ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 8, 2025. Cited figures are marked; the original filing is the authoritative source.

Illumina, Inc. reported first-quarter 2025 results for the quarter ended March 30, 2025, according to a press release furnished as Exhibit 99.1 to this Item 2.02 Form 8-K.

Core Illumina revenue was $1.04 billiona, down 1% from Q1 2024 (flat on a constant currency basis). GAAP operating margin was 15.8% and non-GAAP operating margin was 20.4%. GAAP diluted EPS was $0.82 and non-GAAP diluted EPS was $0.97.

Cash provided by operations was $240 millionb and free cash flow was $208 million. The company repurchased $200 million of shares in the quarter and held $1.24 billion in cash, cash equivalents and short-term investments at quarter end. The company lowered its fiscal 2025 outlook.

Core Illumina revenue is now expected to decline between 1% and 3% on a constant currency basis, down from low single digit growth previously. Management estimates $85 millionc in tariff-related costs, which after actions is an approximate 125 bps reduction in fiscal 2025 operating margin and $0.25 of EPS. Non-GAAP operating margin guidance is approximately 21.5% to 22.0%, down from approximately 23%, and non-GAAP diluted EPS guidance is $4.20 to $4.30, versus a prior March guidance of approximately $4.50.

Reported Greater China revenue is expected to be $165 million to $185 milliond in 2025, with $72 million recognized in Q1 2025. CEO Jacob Thaysen said the outlook weakened due to shifting policy and geopolitical developments, and the company has instituted an incremental $100 million cost reduction program to mitigate potential declines in Greater China revenue and related operating income. The filing also notes the company's inclusion on China's "unreliable entities list" and China's decision not to permit export of sequencing instruments into China as risk factors.

02—Key points

Key Highlights

  1. Core Illumina revenue of $1.04 billion in Q1 2025, down 1% year over year and flat on a constant currency basis.
  2. GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025, compared with GAAP diluted loss per share of $(0.79) in Q1 2024 on a consolidated basis.
  3. Fiscal 2025 Core Illumina revenue guidance lowered to a decline of 1% to 3% on a constant currency basis, from low single digit growth previously.
  4. Non-GAAP diluted EPS guidance cut to $4.20 to $4.30 from approximately $4.50, primarily due to the net impact of tariffs; $85 million in tariff-related costs estimated.
  5. Incremental $100 million cost reduction program instituted to mitigate potential reductions in Greater China revenue and operating income.
  6. Q1 2025 share repurchases of $200 million, with about $1.2 billion remaining under the authorization at quarter end.
  7. Cash provided by operations of $240 million and free cash flow of $208 million in Q1 2025, versus $284 million and $251 million in the prior-year period for Core Illumina.

03—Questions

Frequently Asked Questions

  1. How did Illumina perform in the first quarter of fiscal 2025?

    Core Illumina revenue was $1.04 billion, down 1% from Q1 2024 and flat on a constant currency basis. GAAP operating margin was 15.8% and non-GAAP operating margin was 20.4%. GAAP diluted EPS was $0.82 and non-GAAP diluted EPS was $0.97.

  2. Why did Illumina lower its full-year 2025 guidance?

    According to the filing, the outlook weakened due to shifting policy and geopolitical developments. The company cited the net impact of tariffs, estimating $85 million in tariff-related costs, which after actions is an approximate 125 bps reduction in fiscal 2025 operating margin and $0.25 of EPS. Core Illumina revenue guidance also moved to a decline of 1% to 3% on a constant currency basis.

  3. What is the company's revenue exposure in Greater China?

    Reported revenue from the Greater China region is expected to be $165 million to $185 million in 2025, with $72 million recognized in Q1 2025. Revenue outside Greater China is expected to grow between 0% and 2% on a constant currency basis.

  4. What actions is Illumina taking to protect earnings?

    The company instituted an incremental $100 million cost reduction program to mitigate the impact of a range of potential scenarios for a reduction in revenue and related operating income from its Greater China business. It also repurchased $200 million of shares in Q1 2025 and intends to repurchase incremental shares over the year under its remaining authorization of approximately $1.2 billion.

  5. What risks does the filing highlight for Illumina's business?

    The filing cites uncertainty regarding Illumina's inclusion on the 'unreliable entities list' by Chinese regulatory authorities and China's decision not to permit the export of sequencing instruments into China. It also lists tariffs recently imposed or threatened by the U.S. government and its trading partners, and risks from the GRAIL acquisition litigation.

04—Continue

← View all 8-K filings